<DOC>
	<DOCNO>NCT00226239</DOCNO>
	<brief_summary>The purpose study determine addition unique target agent call Cetuximab ( also know `` C225 '' `` Erbitux '' ) increase effectiveness standard treatment chemotherapy radiation .</brief_summary>
	<brief_title>Docetaxel , Cetuximab Cisplatin Followed Radiation , Cetuximab Cisplatin Head Neck Cancer</brief_title>
	<detailed_description>This research study involve use combination two chemotherapy , cisplatin docetaxel , know shrink head neck cancer commonly use treatment type cancer . This combination follow radiation chemotherapy . The purpose study see whether combination chemotherapy radiation , addition Cetuximab , improve control disease collect information side effect combination therapy may . In addition , biologic factor ( marker ) study may help predict treat head neck cancer patient future .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Stage IIIIVB head neck cancer , site , include unknown primary tumor ( bulky stage II ( T2N0 ) lesions base tongue hypopharynx patient stage II nasopharyngeal cancer also eligible ) Prior study entry resectability alternative treatment option determine team compose Ear , Nose , Throat Surgeon , Radiation Oncologist Medical Oncologist . Stage determination , optimal local treatment , time accord protocol determine evaluation . Unequivocal demonstration distant metastasis ( M1 ) confers ineligibility 2 . Histologically cytologically confirm diagnosis squamous cell poorly differentiate carcinoma , WHO type IIII nasopharynx 3 . Unidimensionallymeasurable disease require ( RECIST ) 4 . No prior chemotherapy , biologic/molecular target therapy ( include prior therapy specifically directly target EGFR pathway ) , radiotherapy head neck cancer 5 . Prior surgical therapy consist incisional excisional biopsy organ spar procedure debulking airway compromise tumor neck dissection patient exist primary tumor ( Any nonbiopsy procedure must take place &gt; 4 week &lt; 3 month initiate protocol treatment ) 6 . ECOG PS 0 1 ; 7 . Organ &amp; marrow function per protocol criterion 8 . Age &gt; =18 year 1 . History severe allergic reaction attribute docetaxel compound similar chemical biologic composition docetaxel , drug formulate polysorbate 80 2 . Uncontrolled intercurrent illness significant history uncontrolled cardiac disease 3 . Receiving investigational agent 4 . No history prior malignancy , exception curatively treat squamous cell basal carcinoma skin situ cervical cancer , malignancy treat curative intent 5year diseasefree survival 5 . Significant baseline sensory motor neurologic deficit ( &gt; grade I neuropathy ) ; 6 . HIVpositive patient 7 . Prior severe infusion reaction monoclonal antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>head</keyword>
	<keyword>neck</keyword>
</DOC>